Rabbit antibodies targeting the following proteins were acquired from Bethyl Laboratories (Montgomery, TX, USA): LEDGF/p75 (Cat# A300-848A), menin (Cat# A300-105A), JPO2 (Cat# A300-846A), and HRP2 (Cat# A304-314A). Rabbit antibodies targeting the following proteins were from Cell Signaling Technology (Danvers, MA, USA): MDR1 (Cat# 13342), IWS1 (Cat# 5681), c-MYC (Cat# 18583), GR (Cat# 12041S), H3K36me2 (Cat# 2091T), and GAPDH (Cat# 5174). Other rabbit antibodies used were against Med-1/TRAPP220 (Abcam, Waltham, MA, USA, Cat# ab243893), PogZ (Aviva Systems Biology, San Diego, CA, USA, Cat# RP39173-P050) and histone H3 (GeneTex, Irvine, CA, USA, Cat# GTX122148). Mouse monoclonal antibodies included ASK1 (Abnova, Walnut, CA, USA Cat# H00010926-M01) JPO2 (Novus Biologicals, Centennial, CO, USA, Cat# NBP2-46198); and horseradish peroxidase (HRP)-conjugated anti-β-actin (Cell Signaling Technologies, Cat# 12620). Human sera containing antinuclear autoantibodies (ANAs) displaying the characteristic monospecific dense fine speckled (DFS) nuclear immunofluorescence pattern that defines immunoreactivity to LEDGF/p75 [16 (link),20 (link),42 (link)], or specific to DNA topoisomerase I (TOPO-1/Scl-70), were from the autoimmune serum collections of Werfen (formerly Inova Diagnostics, San Diego, CA, USA) and the Casiano Laboratory.
Free full text: Click here
